Allogene Therapeutics, Inc. 10-Q filing
Filed 2026-05-13 · Report date 2026-03-31 · 2026
Filing metadata
- Accession number
- 0001628280-26-034585
- Form type
- 10-Q
- CIK
- 0001737287
- Primary document
- https://www.sec.gov/Archives/edgar/data/1737287/000162828026034585/allo-20260331.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for Allogene Therapeutics, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Operating Income | $-46.1M | - | - |
| Net Income | $-42.6M | - | - |
| Eps Basic | -0.18 | - | - |
| Eps Diluted | -0.18 | - | - |
| Cash And Equivalents | $30.3M | - | - |
| Total Assets | $396.0M | - | - |
| Total Liabilities | $117.1M | - | - |
| Shareholders Equity | $278.9M | - | - |
| Operating Cash Flow | $-12.9M | - | - |
| Capital Expenditures | $9,000 | - | - |